Prilosec Rx-to-OTC switch
Executive Summary
AstraZeneca/Proctor & Gamble's Prilosec (omeprazole) prescription to over-the-counter application for prevention of symptoms of frequent heartburn will be reviewed by FDA's Nonprescription Drugs and Gastrointestinal Drugs Advisory Committees June 21. The committees previously voted against a switch for episodic treatment of heartburn but left the prevention claim open (1"The Pink Sheet" Oct. 23, 2000, p. 24). The revised application is for once-daily 20 mg for 14 days. The meeting will be held at the Holiday Inn in Bethesda, Md. at 8 a.m. (Sign up for a webcast at 2FDAAdvisoryCommittee.com)...
You may also be interested in...
Prilosec GERD Indication Suitability For OTC Use Debated By Advisory Cmte.
Gastroesophageal reflux disease is appropriate for OTC treatment, but AstraZeneca/Procter & Gamble's NDA to switch Prilosec OTC is not approvable, FDA's Nonprescription and Gastrointestinal Drugs Advisory Committees voted at a joint meeting Oct. 20.
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.